Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A route to a novel, structurally modified D-myo-inositol 1,3,4,5-tetrakisphosphate analogue, D-2-deoxy-myo-inositol 1,3,4,5-tetrakisphosphate 3, is described, involving as the key steps a selective protection of methyl α-D-glucopyranoside and subsequent catalytic Ferrier rearrangement to a deoxyinosose. Thus, methyl α-D-glucopyranoside was converted by an improved procedure into methyl 4,6-O-benzylidene-α-D-glucopyranoside 4 and thence into methyl 3-O-benzoyl-2-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside 7 without recourse to column chromatography. Compound 7 was converted into methyl 3,4-di-O-benzoyl-2-O-benzyl-6-deoxy-α-D-xylo-hex-5-enopyranoside 12 via methyl 3,4-di-O-benzoyl-2-O-benzyl-6-bromo-6-deoxy-α-D-glucopyranoside 8. Rearrangement of enol ether 12 with mercury(II) trifluoroacetate provided (2S,3R,4S,5R)-2,3-dibenzoyloxy-4-benzyloxy-5-hydroxycyclohexanone 13 and (2S,3A,4S,5S)-2,3-dibenzoyloxy-4-benzyloxy-5-hydroxycyclohexanone 14. Attempts to invert the configuration at position 5 of compound 14 were unsuccessful, but provided a number of discrete products. Reduction of compound 13 and saponification furnished L-1-O-benzyl-3-deoxy-scyll-inositol 23, which was phosphorylated and deprotected to give the target 3.

Type

Journal article

Journal

Journal of the Chemical Society - Perkin Transactions 1

Publication Date

21/06/1996

Pages

1365 - 1372